EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0R1F: Bristol Myers Squibb Co.

19 Dec 2025
LAST:

54.42

CHANGE:
 0.77		OPEN:
53.35		HIGH:
54.56		ASK:
0.00		VOLUME:
5.6K
CHG(%):
1.43		PREV:
53.65		LOW:
52.91		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Dec 2553.3554.5652.9154.425.6K
18 Dec 2553.6554.3953.0653.65977
17 Dec 2554.1055.0053.8354.104.0K
16 Dec 2554.4054.6353.4253.858.0K
15 Dec 2552.7054.3852.5153.4523.4K
12 Dec 2551.5152.9651.0052.543.9K
11 Dec 2551.1851.8750.7151.354.9K
10 Dec 2550.7051.3450.3751.171.0K
09 Dec 2551.5351.9950.4251.539.2K
08 Dec 2552.1052.8251.8351.85154.1K

PROFILE

Name:Bristol Myers Squibb Co.
About:Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Address:Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Website:https://www.bms.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:12.40 
PEG Ratio:-0.54 
Price to Sales:2.19 
Price to Book:3.01 
Profit Margin:0.18 
Operating Margin:0.19 
Return on Assets:0.06 
Return on Equity:0.25 
EPS Ratio:2.82 
DivYield:0.03 
Div/Share:2.46 
Revenue:45.187B 
EBITDA:18.263B 
Shares:1.632B 
Market Cap:88.816B 

TECHNICAL INDICATORS

MA5:53.891.0%
MA10:52.793.1%
MA20:51.076.6%
MA50:47.6914.1%
MA100:47.0615.6%
MA200:48.6111.9%
STO9:84.73 
STO14:90.75 
RSI14:78.62 
MTM14:5.74
ROC14:0.12 
ATR:1.56 
Week High:55.001.1%
Week Low:51.006.7%
Month High:55.001.1%
Month Low:45.3511.9%
Year High:63.1716.1%
Year Low:42.5427.9%
Volatility:26.19 

RECENT DIVIDENDS

Date Amount
03 Oct 2025$0.62
03 Jul 2025$0.62
02 Jul 2025$0.62
04 Apr 2025$0.62
03 Apr 2025$0.62
03 Jan 2025$0.62
02 Jan 2025$0.62
04 Oct 2024$0.60
03 Oct 2024$0.60
05 Jul 2024$0.60